Changeflow GovPing Healthcare & Life Sciences SMARCA2/4 Degrader Compounds and Compositions P...
Routine Notice Added Final

SMARCA2/4 Degrader Compounds and Compositions Patent

Favicon for changeflow.com USPTO Patent Applications - Organic Chemistry (C07D)
Published
Detected
Email

Summary

USPTO published patent application US20260092071A1 for compounds of Formula II as SMARCA2 or SMARCA4 degraders, including their pharmaceutical compositions and uses. The application (No. 19112750) was filed on September 22, 2023, with 14 inventors including Shaomeng Wang and colleagues. This is a publication of a patent application in the field of heterocyclic compounds for potential therapeutic use.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

USPTO published patent application US20260092071A1 covering compounds of Formula II and their pharmaceutical acceptable salts, solvates, or stereoisomers as SMARCA2 or SMARCA4 degraders. The application includes claims for compositions and methods of use. CPC classifications indicate applications in heterocyclic compounds (C07D 487/10, C07D 487/04), pharmaceutical preparations (A61K 31/519, A61K 31/527), with filing date September 22, 2023 under Application No. 19112750.\n\nThis is an informational publication of a patent application; no compliance actions, deadlines, or penalties apply. Companies developing targeted protein degradation therapies or SMARCA2/4 inhibitors should monitor this application for potential freedom-to-operate considerations. The published application provides public notice but does not yet grant patent rights.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF

Application US20260092071A1 Kind: A1 Apr 02, 2026

Inventors

Shaomeng Wang, Lingying Leng, Lin Yang, Wenbin Tu, Liyue Huang, Mi Wang, Wei Jiang, Paul Kirchhoff, Guozhang Xu, Zhenwu Li, Lalgudi Harikrishnan, E. Scott Priestley, Jelena Tosovic, Jeanne Stuckey

Abstract

Described herein are compounds of Formula II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as SMARCA2 or SMARCA4 degraders).

CPC Classifications

C07D 487/10 A61K 31/519 A61K 31/527 A61K 31/5377 A61K 31/541 C07D 471/20 C07D 487/04 C07D 487/20 C07D 491/20 C07D 519/00

Filing Date

2023-09-22

Application No.

19112750

View original document →

Named provisions

Abstract Inventors CPC Classifications

Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 2nd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260092071A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Drug Labeling
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Biotechnology Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!